- Home
- AXIL vs CGTX Comparison
AXIL vs CGTX Comparison
Compare AXIL & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- CGTX
- Stock Information
- Founded
- AXIL 2015
- CGTX 2007
- Country
- AXIL United States
- CGTX United States
- Employees
- AXIL N/A
- CGTX N/A
- Industry
- AXIL Package Goods/Cosmetics
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- AXIL Consumer Discretionary
- CGTX Health Care
- Exchange
- AXIL Nasdaq
- CGTX Nasdaq
- Market Cap
- AXIL 53.3M
- CGTX 53.4M
- IPO Year
- AXIL N/A
- CGTX 2021
- Fundamental
- Price
- AXIL $7.60
- CGTX $2.05
- Analyst Decision
- AXIL
- CGTX Strong Buy
- Analyst Count
- AXIL 0
- CGTX 3
- Target Price
- AXIL N/A
- CGTX $2.83
- AVG Volume (30 Days)
- AXIL 16.5K
- CGTX 8.4M
- Earning Date
- AXIL 10-09-2025
- CGTX 08-07-2025
- Dividend Yield
- AXIL N/A
- CGTX N/A
- EPS Growth
- AXIL 93.65
- CGTX N/A
- EPS
- AXIL 0.29
- CGTX N/A
- Revenue
- AXIL $27,007,463.00
- CGTX N/A
- Revenue This Year
- AXIL N/A
- CGTX N/A
- Revenue Next Year
- AXIL N/A
- CGTX N/A
- P/E Ratio
- AXIL $26.05
- CGTX N/A
- Revenue Growth
- AXIL N/A
- CGTX N/A
- 52 Week Low
- AXIL $3.54
- CGTX $0.22
- 52 Week High
- AXIL $10.75
- CGTX $1.97
- Technical
- Relative Strength Index (RSI)
- AXIL 47.88
- CGTX 78.71
- Support Level
- AXIL $7.55
- CGTX $1.40
- Resistance Level
- AXIL $8.25
- CGTX $1.97
- Average True Range (ATR)
- AXIL 0.76
- CGTX 0.22
- MACD
- AXIL -0.28
- CGTX 0.09
- Stochastic Oscillator
- AXIL 19.69
- CGTX 81.51
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.